EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Cystic Fibrosis and Hemochromatosis Carriers May Be Prone to Glucagon-like Peptide-1 Agonist Pancreatitis: 3 Cases

Guy Itzhak Sydney iD, Tammy Do, William Austin West, Gabriel Ikponmosa Uwaifo iD

JCEM Case Reports · 15.05.2025 · 3 (7)

DOI: 10.1210/jcemcr/luaf104 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 15.05.2025. Verfasst von Guy Itzhak Sydney und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology, Yale School of Medicine, New Haven, CT 06510, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 (GLP-1) agonists are widely used in the management of type 2 diabetes and obesity, with their therapeutic scope expanding to address cardiometabolic and cardiorenal conditions. However, their increasing use has been associated with potential adverse effects, including acute pancreatitis (AP). The exact prevalence of GLP-1 agonist-induced AP remains uncertain and reliable predictors for its onset have yet to be identified. We present 3 cases of class-associated predilection for GLP-1 analog-associated AP in patients with carrier states for hemochromatosis (HC) and cystic fibrosis. Case 1 is a heterozygous carrier for the C282Y HC pathogenic variant. Case 2 is a heterozygous carrier of the Delta F508 deletion of the cystic fibrosis transmembrane regulator (CFTR) gene. Case 3 is compound heterozygous carrier of a single CFTR intron 9 poly T allele pathogenic variant (5T/7T/8T), as well as a single pathogenic variant of the C282Y HC gene. Our observation suggests that carrier states for cystic fibrosis and HC may predispose individuals to GLP-1 agonist-associated AP. Genetic testing for these carrier states should be considered among patients with GLP-1 agonist-associated AP to provide more support and data for this as a potential true risk factor.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 agonistsacute pancreatitischronic pancreatitiscystic fibrosishemochromatosisheterozygous carrier

Autor:innen und Institutionen

  • Section of Endocrinology, Yale School of Medicine, New Haven, CT 06510, USA.
  • Dept of Medicine, Ochsner Medical Center, New Orleans, LA 70121, USA.
  • Section of Pulmonology and Critical Care, University of Southern California Medical Center, Los Angeles, CA 90333, USA.
  • Division of Endocrinology, Department of Medicine, Southern Illinois University School of Medicine, Springfield, IL 62702, USA.

ORCID-Profile: Guy Itzhak Sydney, Gabriel Ikponmosa Uwaifo

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Sydney, G. I., Do, T., West, W. A., & Uwaifo, G. I. (2025). Cystic Fibrosis and Hemochromatosis Carriers May Be Prone to Glucagon-like Peptide-1 Agonist Pancreatitis: 3 Cases. JCEM Case Reports, 3(7). https://doi.org/10.1210/jcemcr/luaf104

Vancouver

Sydney GI, Do T, West WA, Uwaifo GI. Cystic Fibrosis and Hemochromatosis Carriers May Be Prone to Glucagon-like Peptide-1 Agonist Pancreatitis: 3 Cases. JCEM Case Reports. 2025;3(7). doi:10.1210/jcemcr/luaf104

BibTeX
@article{Sydney2025,
  author = {Sydney, Guy Itzhak and Do, Tammy and West, William Austin and Uwaifo, Gabriel Ikponmosa},
  title = {Cystic Fibrosis and Hemochromatosis Carriers May Be Prone to Glucagon-like Peptide-1 Agonist Pancreatitis: 3 Cases},
  journal = {JCEM Case Reports},
  year = {2025},
  volume = {3},
  number = {7},
  doi = {10.1210/jcemcr/luaf104}
}
Kostenlos starten →